

Edgar Filing: ORPHAN MEDICAL INC - Form 8-K/A

ORPHAN MEDICAL INC
Form 8-K/A
June 25, 2003

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K/A

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 10, 2003

ORPHAN MEDICAL, INC.

(Exact name of registrant as specified in its charter)

Delaware ----- (State or other jurisdiction of incorporation)	0-24760 ----- (Commission file number number)	41-1784594 ----- (I.R.S. employer identification)
Suite 250, 13911 Ridgedale Drive, Minnetonka, MN ----- (Address of principal executive offices)	55305 ----- (zip code)	(952) 513-6900 ----- (Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Item 7. Financial Statements and Exhibits

(b) Pro Forma Financial Information

The Company previously reported the sale of Busulfex(R) (busulfan) Injection on June 10, 2003. Pro forma financial statements are attached as Exhibit 99.2 to this Form 8-K/A.

The unaudited pro forma information presented in Exhibit 99.2 presents the Company's statement of operations for the year ended December 31, 2002 and the quarter ended March 31, 2003, assuming the sale of Busulfex(R) (busulfan) Injection reported in Form 8-K dated June 12, 2003 took place effective as of the beginning of each respective fiscal period presented. An unaudited pro forma balance sheet as of March 31, 2003 is also presented and reflects the sale as of March 31, 2003. The unaudited pro forma information presented is for

Edgar Filing: ORPHAN MEDICAL INC - Form 8-K/A

informational purposes only and is not necessarily indicative of the results of operations had the sale of the product as of the dates indicated.

Exhibit List

Exhibit 99.2 - Pro forma Financial Statements.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 25, 2003

ORPHAN MEDICAL, INC.

/s/ Timothy G. McGrath

Timothy G. McGrath
Chief Financial Officer
(duly authorized officer and
principal financial officer)

EXHIBIT INDEX

Exhibit Number	Description
99.2	Pro forma Financial Statements